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despite major advances in assisted reproductive techniques (arT), there remains a considerable risk of developing life-threatening ovarian 
hyperstimulation syndrome (OHSS) as a result of 
supraphysiological stimulation of the ovaries.1 OHSS 
has a reported incidence of 1 to 10% of all arT cycles.2 
Several preventive strategies have been introduced to 
avoid OHSS occurrence or to diminish its severity. 
Coasting is one of the most popular choices among 
physicians for the prevention of OHSS.3–5 On 
the other hand, using a gonadotrophin-releasing 
hormone (GnrH) antagonist as an alternative 
method has been suggested as one of the preferred 
strategies to prevent OHSS in a long protocol.1,6 
However, there are some restrictions on the use 
of antagonist, for example in whose have had an 
inadequate response to the use of antagonists in the 
past, and the lack of accessibility to the antagonist 
in some countries. accordingly, coasting has been 
advocated as an effective approach to avoid OHSS 
in polycystic ovary syndrome (PCOS) patients 
by several investigators.1,7–9 The principle behind 
coasting is based on the phenomenon of apoptosis/
necrosis. by withholding exogenous gonadotropins, 
mature follicles will survive for a few days, while 
the number of smaller follicles will reduce through 
atresia of granulosa cells during apoptosis.9–11 
Interestingly, there is insufficient evidence using 
identical criteria for the application of coasting, and 
many unknowns also remain regarding management 
of this treatment.12 The debate on whether coasting 
has an effect on arT cycle outcomes, such as the 
number and quality of oocytes, is still ongoing.13 
However, the literature suggests that coasting does 
not exert a negative impact on in vitro fertilization 
(IvF) cycle outcome provided that its duration is 
not extended.14–16 
The majority of studies have evaluated the 
impact of coasting on IvF outcome,3 but the effect 
of coasting in patients with different infertility 
causes has not been previously explored. Therefore, 
our study was designed to determine the impact of 
coasting in women at risk of developing OHSS with 
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A B S T R AC T
Objectives: This study aimed to assess the influence of coasting duration on the number 
and quality of oocytes and fertilization rate in male factor infertile women and  those 
with polycystic ovary syndrome (PCOS).  Methods: In this prospective observational 
follow-up study, 114 patients undergoing coasting (53 women with male factor infertility 
and 61 women with PCOS) were evaluated at the royan Institute research Center, Iran, 
between 2010 and 2012.  Results: The results were analyzed according to the coasting 
periods of 1–4 days. In normal females, the number of oocytes retrieved was significantly 
reduced after the second day (p = 0.004). In addition, a statistically significant drop was 
observed in the number of metaphase II oocytes and fertilization rate after the third day 
(p = 0.006 and p = 0.006, respectively). no significant differences were observed in the 
number and quality of oocytes retrieved and fertilization rate with regard to coasting 
days in PCOS patients.  Conclusion: Coasting with duration of more than three days 
should be performed with caution in normal females who are at risk of developing ovarian 
hyperstimulation syndrome.
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male factor infertility (normal women) and women 
with PCOS.
M ET H O D S
In this prospective observational follow-up study, we 
included 114 patients who showed a predisposition 
to developing OHSS during controlled ovarian 
stimulation before IvF/intracytoplasmic sperm 
injection (ICSI) and had undergone coasting at the 
royan Institute research Center, Iran, between June 
2010 and december 2012. 
approval to conduct this study was obtained 
from the Institutional review board of the royan 
Institute research Center and the royan ethics 
Committee. all patients signed an informed consent 
authorizing the use of their information.
The patients were further subdivided into those 
with male factor infertility (n = 53) and PCOS 
(n = 61). The criteria for inclusion in the male 
infertility group were women with partners who 
had asthenospermia or who were candidates for 
percutaneous epididymal sperm aspiration (PeSa) 
and those with 3–4 failed intrauterine insemination 
(IUI) cycles. Patients using sperm retrieved from 
testicular sperm aspiration (TeSa) procedures 
and those using frozen sperm were excluded from 
the study. Women with PCOS who failed to have 
an adequate response to the antagonist in their 
previous induction ovulation were included in the 
study. PCOS was defined by the 2003 rotterdam 
consensus criteria.17
all patients underwent conventional IvF/ICSI 
treatment with the standard long protocol using 
a GnrH agonist (Suprefact, Hoechst, Frankfurt, 
Germany) for pituitary suppression. In addition, a 
starting dose of 112.5 IU of recombinant human 
follicle-stimulating hormone (follitropin alfa pen; 
Gonal-F, merck Serono S.a., Geneva) was used with 
or without menopur (Ferring, Germany) to induce 
ovulation. monitoring of cycles was performed by 
sonography and measurement of estradiol (e2) levels. 
Coasting started when serum e2 was more than 3000 
pg/ml or there were at least 15 follicles with a size 
of 14–16 mm. during coasting, which was not more 
than four days, gonadotropin administration was 
withheld, whereas GnrH agonist was maintained. 
Furthermore, daily monitoring by sonography and 
serum e2 measurements was continued until e2 
concentrations decreased by 50% of maximum 
rising. Ovarian puncture was performed 34–36 
hours after human chorionic gonadotropin 
(hCG) administration.
The coasting duration was determined as 
the number of days from the last injection of 
gonadotropin to the hCG-day administration. The 
fertilization rate was calculated as the number of 
oocytes with two pronuclei divided by the number 
of injected oocytes when ICSI was performed and by 
all intact oocytes retrieved when IvF was performed. 
The results were analyzed according to the coasting 
periods for 1–4 days, separately in each group of 
infertile women with male factor and PCOS.
The statistical comparisons were performed using 
one-way analysis of variance (anOva), Kruskal-
Wallis nonparametric analysis of variance and chi-
square when appropriate. The results were reported 
as median  (IQr; interquartile range). a p-value 
< 0.050 was considered statistically significant. data 
analysis was performed using SPSS Statistics (SPSS 
Statistics Inc., Chicago, US) version 18.0. 
R E SU LTS
In this study, the data of 114 women undergoing 
coasting were analyzed. Coasting was performed 
in 53 normal patients and 61 patients with PCOS. 
The demographic and hormonal levels compared 
with the duration of coasting by days (1–4) 
are presented separately in male factor infertile 
women and women with PCOS [Table 1]. There 
were no statistically significant differences between 
different days of coasting with regard to age, body 
mass index (bmI), and basal hormone levels. When 
comparing the e2 level at the start of coasting 
between coasting days, a statistically significant 
difference was observed in each group of normal 
women and women with PCOS (p = 0.036 and p = 
0.005, respectively).
In normal females, the number of oocytes 
retrieved was significantly reduced after the 
second day of coasting (p = 0.004). additionally, 
a statistically significant drop was observed in 
the number of metaphase II (mII) oocytes and 
fertilization rate after the third day (p = 0.006 and 
p = 0.006, respectively). On the other hand, in PCOS 
patients, no statistically significant differences were 
revealed between different days of coasting regarding 
the number and quality of oocytes retrieved and 
fertilization rate [Table 2].
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D I S C U S S I O N 
OHSS is a serious complication related to ovulation 
induction which is sometimes seen in low-risk 
patients, but it is more likely to occur in high-risk 
patients.3 PCOS is a well-known risk factor for 
OHSS.12,13,18 despite the widespread use of coasting 
Table 1: Comparison of age, BMI, basal hormone levels, and stimulation days of women with male infertility 
and PCOS according to the number of days coasting.
Coasting, days p-value
1 2 3 4
Male infertility
Patients, n 10 16 19 8
age, years 28.5 (25.2–32.7) 26.0 (24.0–27.0) 30.0 (25.0–33.0) 28.0 (23.7–32.7) 0.260
bmI, kg/m2 26.1 (23.6–28.8) 25.3 (21.7–27.0) 22.6 (19.3–25.4) 22.9 (19.2–25.2) 0.090
FSH, mIU/ml 4.3 (2.9–6.6) 6.0 (4.6–7.0) 6.6 (5.2–7.4) 5.6 (3.8–7.1) 0.311
lH, mIU/ml 2.9 (1.6–8.1) 6.1 (3.9–8.7) 5.0 (2.7–8.6) 5.1 (4.1–7.9) 0.396
TSH, mIU/ml 1.3 (0.7–1.8) 1.7 (1.1–2.4) 1.8 (1.3–3.8) 1.8 (0.5–3.6) 0.376
Prl, ng/ml 18.9 (14.6–566.2) 14.9 (9.5–28.0) 38.5 (15.2–247.0) 35.1 (11.0–320.2) 0.400
e2 at start of coasting, 
pg/ml
2639.0
(1036.0–4068.0)
4332.0
(4006.0–5164.0)
4856.0
(3919.0–6517.0)
5390.0
(4728.0–7809.0)
0.036
e2 at hCG day, pg/ml 2087.0
(1793.0–4434.0)
2925.0
(1663.0–4411.0)
3265.0
(2482.0–6581.0)
4204.0
(627.0–5682.0)
0.573
PCOS
Patients, n 23 20 11 7
age, years 31.0 (25.7–35.2) 31.0 (28.0–33.0) 36.0 (29.0–38.0) 30 (29.0–32.0) 0.425
bmI, kg/m2 24.8 (23.8–29.2) 24.4 (22.7–27.6) 25.3 (21.2–26.4) 25.5 (24.3–28.4) 0.583
FSH, mIU/ml 7.3 (4.5–8.0) 4.2 (3.7–6.7) 5.0 (2.6–6.6) 4.0 (2.9–4.4) 0.261
lH, mIU/ml 5.5 (4.0–9.8) 7.6 (2.1–10.6) 6.8 (3.0–18.0) 6.3 (3.3–9.0) 0.881
TSH, mIU/ml 1.8 (0.6–2.2) 2 (1.0–2.8) 1.8 (0.8–2.6) 1.5 (0.8–3.0) 0.756
Prl, ng/ml 22.9 (14–168) 15 (10.1–133.5) 20.1 (4.6–162.5) 19.9 (9.7–286.0) 0.774
e2 at start of coasting, 
pg/ml
3462.0
(3163.0–4336.0)
3353.0
(2059.0–4382.0)
5182.0
(4360.0–7632.0)
5358.0
(5263.0–6772.0)
0.005
e2 at hCG day, pg/ml 2501.0
(1774.0–4514.0)
3419.0
(2390.0–5551.0)
5061.0
(2549.0–6710.0)
2203.0
(1110.0–4324.0)
0.109
Values given as median (IQR). The statistical comparisons were performed by Kruskal-Wallis test. PCOS: polycystic ovarian syndrome; BMI: body mass index; FSH: 
follicle stimulating hormone; LH: luteinizing hormone; TSH: thyroid stimulating hormone; PRL: prolactin; E2: estradiol; hCG: human chorionic gonadotropin. 
Table 2: IVF outcome according to the duration of coasting in women with male infertility and PCOS.
Coasting, days p-value
1 2 3 4
Male infertility
Patients, n 10 16 19 8
Oocyte, mean±Sd 18.6±2.4a 15.3±1.9ab 13.1±1.0b 7.1±1.3c 0.002
mII, mean±Sd 16.1±2.2a 13.2±1.6 a 11.8±0.9 a 6.7±1.3b 0.006
Fertilization rate, % (n) 60.2 (97/161) a 63.0 (136/216) a 57.3 (129/225) a 37.0 (20/54)b 0.006
PCOS
Patients, n 23 20 10 7
Oocyte 14.0 (10.0–20.0) 14.5 (8.2–18.5) 10.5 (8.7–20.0) 9.0 (6.0–17.0) 0.433
mII 11.0 (8.0–16.0) 11.5 (4.5–15.0) 9.5 (6.0–19.2) 7.0 (6.0–16.0) 0.698
Fertilization rate, % (n) 63.7 (235/369) 56.5 (169/299) 65.2 (75/115) 63.2 (43/68) 0.202
Values given as median (IQR) unless otherwise stated; a, b, c: The same letter in each row indicates no significant difference between days at 0.050 level. IVF: in vitro 
fertilization; PCOS: polycystic ovarian syndrome; MII: metaphase II.
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treatment by physicians,3,4 our findings do not 
provide explicit evidence that coasting is useful in 
the prevention of OHSS in all patients undergoing 
controlled ovarian hyperstimulation with any cause 
of infertility.
many studies have addressed the effect of 
coasting on controlled ovarian hyperstimulation 
(COH) cycles.9,12,15,19,20 a large body of evidence 
has advocated coasting as an effective method for 
preventing OHSS in high-risk groups without 
compromising pregnancy outcome.7–9 In contrast, 
others have shown a decline in the number of oocytes 
obtained and oocyte quality in coasted cycles.19,21,22 
a recent Cochrane review demonstrated that 
randomized controlled trials performed for the 
prevention of OHSS by coasting were not powerful 
enough to confirm the efficiency of this method.3,20
based on clinician experience, e2 levels for 
initiation of coasting is varied.3,5 a retrospective 
analysis of 608 patients demonstrated that the initial 
level of e2 to start coasting might have an impact on 
oocyte quality.3 Furthermore, a recent review study 
emphasized that coasting should be initiated with a 
serum e2 level greater than 3000 pg/ml.23
Our study revealed that coasting treatment and 
success varies with cause of infertility. accordingly, 
in normal females, coasting with duration of more 
than two days is likely to exert an adverse effect on 
the number of oocytes, and coasting for more than 
three days negatively affects oocyte quality and 
fertilization rate. However, in contrast, coasting can 
be safely applied to infertile PCOS women in light 
of OHSS potential risks without compromising the 
outcome. many investigators have used different 
criteria to specify the time of starting and ending 
of coasting and they have reported different results 
for the effect of coasting period on the prevention 
of OHSS and reproductive outcomes.1,8,16,19,24 Some 
authors believe that too short a period of coasting 
may not be effective in preventing OHSS, whereas 
too long a period may have a less satisfactory 
outcome in terms of oocyte quality and endometrial 
receptivity.5,15,23 despite the debate over the coasting 
effect, there has almost been an agreement among 
studies that oocyte quality and pregnancy outcome 
are adversely affected after four days of coasting.11,16,19
The observed differences between our study and 
previous studies could be due to our patient selection 
according to the cause of infertility. In general, 
physiological mechanisms are probably involved 
in the adverse effects of coasting on outcome of 
treatment cycle in normal women compared to 
women with PCOS. This, in turn, may indicate 
that PCOS patients show less sensitivity to the 
manipulation occurring during coasting. This may be 
explained by the critical role of luteinizing hormone 
(lH) in the final stages of follicular maturation. The 
lH receptors of the follicles decrease following the 
coasting process, and this reduction is expected to be 
severe with longer coasting periods. Consequently, 
these follicles with a low number of functional lH 
receptors have a poor response to exogenous hCG, 
and so, final maturation will not be obtained.9,13 On 
the other hand, granulosa cells from polycystic ovaries 
contain higher number of lH receptors compared 
with normal granulosa cells.25 accordingly, despite 
the loss of receptors following coasting, in women 
with PCOS there are relatively adequate receptors 
for supporting final maturation, whereas in normal 
women these endocrine changes are not tolerable by 
follicles. as our study showed, in women with male 
factor infertility, there was a decreasing trend in the 
number of oocytes obtained, and oocyte quality and 
fertilization rate with regard to the coasting days 
(even with periods less than four days).
C O N C LU S I O N
Our results indicate that before making important 
treatment decisions in infertile patients at risk of 
developing OHSS, the impact of an infertility 
diagnosis should be considered. accordingly, 
coasting for more than three days should be 
performed with caution in normal women who are at 
risk of developing OHSS. In this respect, an attempt 
to determine a recommended protocol for normal 
women, coasting for one or two days combined with 
another preventive method appears to be the most 
desirable option for avoiding OHSS. Obviously, 
the lack of research in this area and the potentially 
sensitive nature of OHSS makes it difficult to draw 
definite conclusions and further studies with a larger 
population is suggested.
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